RIP1 Regulates Mitochondrial Fission during Skeletal Muscle Ischemia Reperfusion Injury

Yu Cao1, Shunli Chen1, Xiangqing Xiong1

  • 1Department of Anesthesiology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang Province, China.

Abstract

Insights

Receptor-interacting protein 1 (RIP1) acts upstream of dynamin-related protein-1 (Drp1) in skeletal muscle ischemia-reperfusion (IR) injury. Inhibiting RIP1 or Drp1 reduces muscle damage and mitochondrial fragmentation during IR.

Area of Science:

  • Muscle Physiology
  • Cellular Biology
  • Pathology

Background:

  • Dynamin-related protein-1 (Drp1)-mediated mitochondrial fission is linked to ischemia-reperfusion (IR) injury.
  • The role of necroptosis, particularly receptor-interacting protein 1 (RIP1) kinase, in this process is implied but not fully understood.

Purpose of the Study:

  • To investigate the upstream role of RIP1 in Drp1-mediated mitochondrial fission during skeletal muscle IR.
  • To determine the effects of RIP1 and Drp1 inhibition on muscle damage and oxidative stress.

Main Methods:

  • Thirty rats were divided into sham-operated, IR, Nec-1 (RIP1 inhibitor), Mdivi-1 (Drp1 inhibitor), and vehicle control groups.
  • Soleus muscles were analyzed for histopathology, mitochondrial morphology, RIP1 and Drp1 (total and phosphorylated) expression, oxidative stress markers, and muscle damage biomarkers.

Main Results:

  • Ischemia-reperfusion induced significant mitochondrial fragmentation, increased oxidative stress, and elevated muscle damage biomarkers in soleus muscles.
  • Both Nec-1 and Mdivi-1 treatments attenuated these IR-induced detrimental effects.
  • RIP1 and phosphorylated Drp1 (p-Drp1 Ser616) levels were upregulated post-IR, with Nec-1 attenuating RIP1 and p-Drp1, while Mdivi-1 only reduced p-Drp1.

Conclusions:

  • Receptor-interacting protein 1 (RIP1) kinase functions upstream of Drp1-mediated mitochondrial fission in the execution of necroptosis during skeletal muscle IR injury.
  • Targeting RIP1 or Drp1 may offer therapeutic strategies for mitigating skeletal muscle IR injury.